Pharvaris PHVS
NASDAQ PHVS
$36.16 +0.50 (+1.40%)
As of: Sep 4, 2026 · 2:33 PM EDT

Pharvaris (PHVS) Operating Income Growth (3y) (2023 - 2026)

Analysis

Pharvaris (PHVS) Operating Income Growth (3y) (2023 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Op. Inc Growth (3y) (Qtr)
1 Vertex Pharmaceuticals 138.77 Bn 130.92 Bn 2.84 Bn 6.70%
2 Regeneron Pharmaceuticals 85.51 Bn 77.52 Bn 3.93 Bn 8.36%
3 Argenx Se 63.51 Bn 58.32 Bn 1.37 Bn 89.72%
4 Moderna 58.20 Bn 53.06 Bn 52.00 Mn 24.14%
5 Revolution Medicines 44.04 Bn 44.04 Bn - -
6 BeOne Medicines 39.99 Bn 34.89 Bn 1.53 Bn 44.54%
7 Alnylam Pharmaceuticals 35.45 Bn 32.14 Bn 992.69 Mn 44.34%
8 Royalty Pharma 28.40 Bn 27.56 Bn - -18.82%
9 Insmed 27.44 Bn 26.28 Bn 358.27 Mn 81.27%
10 Pharvaris 2.15 Bn 1.78 Bn 85,072.10 -32.24%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -32.24%
Mar 31, 2026 -31.83%
Dec 31, 2025 22,241.16%
Sep 30, 2025 -27.12%
Jun 30, 2025 -69.40%
Mar 31, 2025 -26.83%
Dec 31, 2024 26,922.89%
Sep 30, 2024 -38.35%
Jun 30, 2024 -20.39%
Mar 31, 2024 -29.13%
Dec 31, 2023 -35.88%
Sep 30, 2023 -57.30%
Jun 30, 2023 -55.56%
Mar 31, 2023 -84.82%